KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Gp-100 as a Novel Therapeutic Target in Uveal Melanoma.

Daniel Martinez-Perez, David Viñal, Isabel Solares, Enrique Espinosa, Jaime Feliu

Cancers (Basel) 13(23) 5968

PMID34885078
PMCIDPMC8656894
DOI10.3390/cancers13235968
发表日期2021-12-10
摘要

摘要

Uveal melanoma is a rare neoplasm with poor prognosis in the metastatic setting. Unlike cutaneous melanoma, treatment with kinase inhibitors or immune checkpoint inhibitors is not effective. Glycoprotein 100 (Gp-100) is a protein highly expressed in melanocytes and melanoma that has recently been effectively targeted by tebentafusp, a first-in-class bispecific protein of the immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs) family. Tebentafusp targets tumor cells that express a peptide of Gp-100 presented by HLA*A0201, creating an immune synapse that kills targeted tumor cells. Recently, a randomized phase III trial reported an overall survival benefit for tebentafusp in patients with untreated metastatic uveal melanoma. The aim of this comprehensive review is to summarize evidence of Gp-100 as a therapeutic target in melanoma, and the preclinical and clinical development of tebentafusp as a novel therapeutic strategy for patients with uveal melanoma.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。